Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

468 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The EHA Research Roadmap: Malignant Lymphoid Diseases.
Dreyling M, André M, Gökbuget N, Tilly H, Jerkeman M, Gribben J, Ferreri A, Morel P, Stilgenbauer S, Fox C, Maria Ribera J, Zweegman S, Aurer I, Bödör C, Burkhardt B, Buske C, Dollores Caballero M, Campo E, Chapuy B, Davies A, de Leval L, Doorduijn J, Federico M, Gaulard P, Gay F, Ghia P, Grønbæk K, Goldschmidt H, Kersten MJ, Kiesewetter B, Landman-Parker J, Le Gouill S, Lenz G, Leppä S, Lopez-Guillermo A, Macintyre E, Mantega MVM, Moreau P, Moreno C, Nadel B, Okosun J, Owen R, Pospisilova S, Pott C, Robak T, Spina M, Stamatopoulos K, Stary J, Tarte K, Tedeschi A, Thieblemont C, Trappe RU, Trümper LH, Salles G. Dreyling M, et al. Among authors: ferreri a. Hemasphere. 2022 May 19;6(6):e726. doi: 10.1097/HS9.0000000000000726. eCollection 2022 Jun. Hemasphere. 2022. PMID: 35620592 Free PMC article. No abstract available.
Chronic lymphocytic leukemia.
Ghia P, Ferreri AM, Caligaris-Cappio F. Ghia P, et al. Crit Rev Oncol Hematol. 2007 Dec;64(3):234-46. doi: 10.1016/j.critrevonc.2007.04.008. Epub 2007 Jun 1. Crit Rev Oncol Hematol. 2007. PMID: 17544290 Review.
Targets and treatments in primary CNS lymphoma.
von Roemeling C, Ferreri AJM, Soussain C, Tun HW, Grommes C. von Roemeling C, et al. Among authors: ferreri ajm. Leuk Lymphoma. 2024 Apr 24:1-13. doi: 10.1080/10428194.2024.2342560. Online ahead of print. Leuk Lymphoma. 2024. PMID: 38659230 Review.
Marginal zone lymphoma international prognostic index: a unifying prognostic index for marginal zone lymphomas requiring systemic treatment.
Arcaini L, Bommier C, Alderuccio JP, Merli M, Fabbri N, Nizzoli ME, Maurer MJ, Tarantino V, Ferrero S, Rattotti S, Talami A, Murru R, Khurana A, Mwangi R, Deodato M, Cencini E, Re F, Visco C, Feldman AL, Link BK, Delamain MT, Spina M, Annibali O, Pulsoni A, Ferreri AJM, Stelitano CC, Pennese E, Habermann TM, Marcheselli L, Han S, Reis IM, Paulli M, Lossos IS, Cerhan JR, Luminari S. Arcaini L, et al. Among authors: ferreri ajm. EClinicalMedicine. 2024 Apr 11;72:102592. doi: 10.1016/j.eclinm.2024.102592. eCollection 2024 Jun. EClinicalMedicine. 2024. PMID: 38633575 Free PMC article.
Liquid biopsy for improving diagnosis and monitoring of CNS lymphomas: a RANO review.
Nayak L, Bettegowda C, Scherer F, Galldiks N, Ahluwalia M, Baraniskin A, von Baumgarten L, Bromberg JEC, Ferreri AJM, Grommes C, Hoang-Xuan K, Kühn J, Rubenstein JL, Rudà R, Weller M, Chang SM, van den Bent MJ, Wen PY, Soffietti R. Nayak L, et al. Among authors: ferreri ajm. Neuro Oncol. 2024 Apr 10:noae032. doi: 10.1093/neuonc/noae032. Online ahead of print. Neuro Oncol. 2024. PMID: 38598668
Germinal Center Dark Zone harbors ATR-dependent determinants of T-cell exclusion that are also identified in aggressive lymphoma.
Cancila V, Morello G, Bertolazzi G, Chan AS, Bastianello G, Paysan D, Jaynes PW, Schiavoni G, Mattei F, Piconese S, Revuelta MV, Noto F, De Ninno A, Cammarata I, Pagni F, Venkatachalapathy S, Sangaletti S, Di Napoli A, Vacca D, Lonardi S, Lorenzi L, Ferreri AJM, Belmonte B, Varano G, Colombo MP, Bicciato S, Inghirami G, Cerchietti L, Ponzoni M, Zappasodi R, Facchetti F, Foiani M, Casola S, Jeyasekharan AD, Tripodo C. Cancila V, et al. Among authors: ferreri ajm. Res Sq [Preprint]. 2024 Mar 18:rs.3.rs-4093618. doi: 10.21203/rs.3.rs-4093618/v1. Res Sq. 2024. PMID: 38562878 Free PMC article. Preprint.
Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE study.
Chiappella A, Casadei B, Chiusolo P, Di Rocco A, Ljevar S, Magni M, Angelillo P, Barbui AM, Cutini I, Dodero A, Bonifazi F, Tisi MC, Bramanti S, Musso M, Farina M, Martino M, Novo M, Grillo G, Patriarca F, Zacchi G, Krampera M, Pennisi M, Galli E, Martelli M, Ferreri AJM, Ferrari S, Saccardi R, Bermema A, Guidetti A, Miceli R, Zinzani PL, Corradini P. Chiappella A, et al. Among authors: ferreri ajm. Leukemia. 2024 May;38(5):1107-1114. doi: 10.1038/s41375-024-02213-x. Epub 2024 Mar 8. Leukemia. 2024. PMID: 38459167 Free PMC article.
Predicting outcomes in CNS lymphoma with ctDNA.
Winter JN, Ferreri AJM. Winter JN, et al. Among authors: ferreri ajm. Blood. 2024 Feb 8;143(6):478-480. doi: 10.1182/blood.2023023008. Blood. 2024. PMID: 38329774 No abstract available.
MYC rearrangements in HIV-associated large B-cell lymphomas: EUROMYC, a European retrospective study.
Pagani C, Rusconi C, Dalla Pria A, Ravano E, Schommers P, Bastos-Oreiro M, Verga L, Gini G, Spina M, Arcaini L, Steffanoni S, Dalu D, Crucitti L, Lorenzi L, Balzarini P, Cattaneo C, Bongiovanni L, Rosenwald A, Facchetti F, Bower M, Ferreri AJM, Rossi G, Tucci A, Re A. Pagani C, et al. Among authors: ferreri ajm. Blood Adv. 2024 Feb 27;8(4):968-977. doi: 10.1182/bloodadvances.2023010704. Blood Adv. 2024. PMID: 38207206 Free PMC article.
IELSG30 phase 2 trial: intravenous and intrathecal CNS prophylaxis in primary testicular diffuse large B-cell lymphoma.
Conconi A, Chiappella A, Ferreri AJM, Stathis A, Botto B, Sassone M, Gaidano G, Balzarotti M, Merli F, Tucci A, Vanazzi A, Tani M, Bruna R, Orsucci L, Cabras MG, Celli M, Annibali O, Liberati AM, Zanni M, Ghiggi C, Pisani F, Pinotti G, Dore F, Esposito F, Pirosa MC, Cesaretti M, Bonomini L, Vitolo U, Zucca E. Conconi A, et al. Among authors: ferreri ajm. Blood Adv. 2024 Mar 26;8(6):1541-1549. doi: 10.1182/bloodadvances.2023011251. Blood Adv. 2024. PMID: 38181782 Free PMC article. Clinical Trial.
468 results